| Name | Livmoniplimab |
|---|
| Description | Livmoniplimab (ABBV-151; ARGX-115) is a potent humanized anti-LRRC32 (GARP)/TGFβ1 monoclonal antibody. Livmoniplimab blocks LRRC32-mediated activation of latent TGFβ1. Livmoniplimab has the potential for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |